Melanoma incidence and mortality trends in Sweden

JAMA Dermatology

2024-09-09

(Press-News.org) About The Study: The findings of this cohort study showed a significant recent downward trend in both melanoma incidence and melanoma mortality in the age group 30 to 49 years in Sweden. The reasons for these declines are unclear but may include UV protection, public health campaigns, changing population demographics, and the introduction of effective melanoma treatment. None of these possibilities were evaluated; further study is needed.

Corresponding Author: To contact the corresponding author, Hildur Helgadottir, MD, PhD, email hildur.helgadottir@sll.se.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamadermatol.2024.3514)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being presented at the European Society for Medical Oncology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.3514?guestAccessKey=63581074-cfbd-45ae-80e2-e9605b09b936&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090824

END

ELSE PRESS RELEASES FROM THIS DATE:

Breaking the trend: Skin cancer incidence in young adults declines

2024-09-09

The risk of skin cancer, malignant melanoma, now appears to be decreasing in Sweden - at least in those under 50, according to a new study. “We can see a trend break in young adults around 2015 where the incidence curves are falling,” says first author Hildur Helgadottir, senior consultant and associate professor of oncology at the Department of Oncology-Pathology, Karolinska Institutet. She and her research colleagues have analyzed data from the Swedish Melanoma Registry and followed melanoma incidence and mortality for different age segments over time. This means that they have compared individuals in a certain age range at one ...

ChatGPT outperformed trainee doctors in assessing complex respiratory illness in children

2024-09-09

The chatbot ChatGPT performed better than trainee doctors in assessing complex cases of respiratory disease in areas such as cystic fibrosis, asthma and chest infections in a study presented at the European Respiratory Society (ERS) Congress in Vienna, Austria [1]. The study also showed that Google’s chatbot Bard performed better than trainees in some aspects and Microsoft’s Bing chatbot performed as well as trainees. The research suggests that these large language models (LLMs) could be used to support trainee doctors, nurses and general practitioners to triage patients more quickly and ease pressure on health services. The ...

Night owls are more likely to develop type 2 diabetes – and it’s not just because of an unhealthy lifestyle, Dutch study finds

2024-09-09

Night owls have a higher BMI, larger waists, more hidden body fat and are almost 50% more likely to develop type 2 diabetes (T2D) than those who go to bed earlier, new research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), has found. Lead researcher Dr Jeroen van der Velde, of Leiden University Medical Centre, Leiden, Netherlands, says: “Previous studies have indicated that a late chronotype – preferring to go to bed late and wake up later – is associated with an unhealthy lifestyle. Late chronotypes are ...

Air travel may affect insulin pump delivery in people with type 1 diabetes

2024-09-09

Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept). “We investigated the effect atmospheric pressure changes during flight can have on insulin pumps following concerns that glucose levels may drop below the normal ranges during or immediately after flights,” explained lead author Dr Ka Siu Fan from the Royal Surry County Hospital and University ...

Fruit and oats raise risk of type 1 diabetes but berries provide protection, research suggests

2024-09-09

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), shows that eating fruit, oats and rye in childhood is associated with a higher risk of developing type 1 diabetes (T1D). Eating berries, however, is linked to lower odds of developing the condition. T1D is an autoimmune condition in which the immune system attacks and destroys the insulin-producing islet cells in the pancreas. This prevents the body from producing enough of the hormone insulin to properly regulate blood sugar levels. What triggers the immune system’s attack is unknown but is thought to involve a combination ...

Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found

2024-09-09

Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear. Glucocorticoids (sometimes known as steroids) fight inflammation and are used to treat a wide range of inflammatory and autoimmune conditions, including asthma, rheumatoid arthritis, cancers and other medical problems. While they can be very effective in decreasing inflammation, glucocorticoids have many adverse effects including ...

Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC

2024-09-08

(San Diego, Calif--September 8, 2024, 10:05 a.m. PCT) – New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery compared to those who received only neoadjuvant nivolumab plus chemotherapy. The data was reported at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. This is the first analysis of individual patient-level data from two phase 3 trials, CheckMate 77T and CheckMate 816, to examine which patients may derive benefit from ...

PanCan nodule management protocol more effective than LungRADSv1.1 method

2024-09-08

(San Diego, Calif.--September 8, 2024, 10:05 a.m. PCT) – New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in triaging lung cancer screening participants compared to the LungRADSv1.1 approach. Specifically, PanCan showed improved risk stratification and reduced the number of low-dose computed tomography(CT) scans required. The research was reported by Dr. Annette McWilliams, Fiona Stanley Hospital, Australia at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer. The ...

Normalized membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes in TROPION-Lung 01

2024-09-08

(San Diego, Calif.--September 8, 2024, 10:05 a.m. PCT) – New data presented today demonstrate that TROP2 expression as measured by quantitative continuous scoring (QCS), a computational pathology approach, is a promising predictor of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated with the TROP2 antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). The data showed that patients with TROP2 positivity, as determined by QCS, experienced improved efficacy with Dato-DXd compared to patients receiving docetaxel ...

Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study

2024-09-08

(San Diego, Calif--September 8, 2024, 8:30 a.m.) — Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer. The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer. The HARMONi-2 study randomized 398 patients ...

Melanoma incidence and mortality trends in Sweden

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: